Boehringer Ingelheim to acquire STEAG microParts GmbH
STEAG microParts' core product is the innovative Respimat® Soft MistTM Inhaler which was co-developed together with Boehringer Ingelheim. This novel medicinal inhaler, which generates a slow-moving long-lasting soft mist through purely mechanical means, allows for excellent penetration of the lungs. Respimat® Soft MistTM Inhaler offers all patients with asthma or COPD (chronic-obstructive airways disease) effective medication in precise doses.
"The acquisition of STEAG microParts fits very well into our production strategy," explained Dr Hans-Jürgen Leuchs, responsible within the Boehringer Ingelheim Board of Managing Directors for production and technology. "We see Respimat® Soft MistTM Inhaler as the inhalation device of the future; it is to be tested in clinical studies successively with different respiratory products. We thank STEAG microParts for the excellent cooperation in recent years and now look forward to having full control of the entire production chain following the acquisition. In addition, the expertise in development and production at STEAG microParts, especially in microsystem technology, will be an excellent supplement to our development activities in the field of innovative Drug Delivery".
Most read news
Other news from the department business & finance
Get the analytics and lab tech industry in your inbox
From now on, don't miss a thing: Our newsletter for analytics and lab technology brings you up to date every Tuesday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.